Research and Markets has announced the addition of the "Osteosarcoma - Pipeline Review, H2 2016" report to their offering.
The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.
Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.
Osteosarcoma pipeline therapeutics constitutes close to 41 molecules. Out of which approximately 26 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 12, 5, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 3, 3 and 5 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/78w3wc/osteosarcoma
Related Topics: Oncology Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005887/en/Business Wire
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.